Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with a specific reporting date of February 24, 2021. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Insider Name | Dr. H. Barron (Chief Scientific Officer and President, R&D) |
| Transaction Date | February 22, 2021 |
| Exchange | New York Stock Exchange (XNYS) |
| Price per ADS | $34.44 |
| Total Volume | 1,442.249 ADSs (1,223.249 via Supplemental Savings Plan; 219 via 401(k) Plan) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses the acquisition of shares by an executive officer through company-sponsored savings plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a completed transaction.
Key Facts for Investor Verification
- Dr. H. Barron, a senior executive, acquired a total of 1,442.249 GSK ADSs on February 22, 2021.
- The acquisitions were executed at a price of $34.44 per ADS.
- The transactions were split between the GSK Executive Supplemental Savings Plan (1,223.249 shares) and the GSK 401(k) Plan (219 shares).
- This filing does not contain financial performance data for the company.